1.Prevalence of left main coronary artery disease among patients referred to multislice computed tomography coronary examinations.Gemici G, Guneysu T, Eroğlu E, Bayrak F, Sevinc D, Aytaclar S, Kaya Z, Mutlu B, Degertekin M.
2.Echocardiographic predictors of severe heart failure symptoms in hypertrophic cardiomyopathy patients with sinus rhythmBayrak F, Kahveci G, Degertekin M, Mutlu BTrials. 2008 Feb 29;9:11
3.Diagnostic performance of 64-slice stenosis.computed tomography coronary angiography to detect significant coronary arteryBayrak F, Guneysu T, Gemici G, Sevinc D, Mutlu B, Aytaclar S, Degertekin M.Acta Cardiol. 2008 Feb;63(1):11-7
4.Tissue Doppler imaging to predict clinical course of patients with hypertrophic cardiomyopathy.Bayrak F, Kahveci G, Mutlu B, Sonmez K, Degertekin Eur J Echocardiogr. 2008 Mar;9(2):278-83.
5.Safety and efficacy of patient preparation with intravenous esmolol before 64-slice computed tomography coronary angiography.Degertekin M, Gemici G, Kaya Z, Bayrak Guneysu T, Sevinc D, Mutlu B, Aytaçlar S. Coron Artery Dis. 2008 Feb;19(1):33-6..
6.Prognostic value of N-terminal pro-B-type natriuretic peptide in patients with active infective endocarditis.Kahveci G, Bayrak F, Mutlu B, Bitigen A, Karaahmet T, Sonmez K, Izgi A, Degertekin M, Basaran Y.Am J Cardiol. 2007 May 15;99(10):1429-33. Epub 2
7.Can multidetector CT angiography detect coronary artery dissection?Vural M, Aksit Z, Kovanlikaya I, Degertekin M, Demirtas E.Tex Heart Inst J. 2007;34(3):388-9.
8.Usefulness of N-terminal pro-B-type natriuretic peptide to predict clinical course in patients with hypertrophic cardiomyopathy.Mutlu B, Bayrak F, Kahveci G, Degertekin M, Eroglu E, Basaran Y.Am J Cardiol. 2006 Dec 1;98(11):1504-6. Epub 2006 Oct 12
9.Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial.Tanabe K, Serruys PW, Degertekin M, Grube E, Guagliumi G, Urbaszek W, Bonnier J, Lablanche JM, Siminiak T, Nord
10.In-hospital versus out-of-hospital cardiac arrest complicating myocardial infarction: survival after percutaneous coronary revascularization.Lee CH, Lemos PA, Degertekin M, Saia F, Tanabe K, Serruys PW.(Int J Cardiol. 2005 Feb 15;98(2):359-60.)
11.Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the rapamycin eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry.Saia F, Lemos PA, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, S
12.Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. Tanabe K, Hoye A, Lemos PA, Aoki J, Arampatzis CA, Saia F, Lee CH, Degertekin M, Hofma SH, Sianos G, McFadden E, Smits PC, van der Giessen WJ, de Feyt
13.Effectiveness of sirolimus-eluting stent implantation for coronary narrowings <50% in diameterHoye A, Lemos PA, Arampatzis CA, Saia F, Tanabe K, Degertekin M, Daemen J, Smits PC, McFadden E, Hofma SH, Sianos G, de Feyter P, van der Giessen WJ, van Do
14.Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo NarrowingsTanabe K, Hoye A, Lemos PA, Arampatzis CA, Saia F, Lee CH, Degertekin M, Hofma SH, Sianos G, McFadden E, Smits PC, van der Giessen WJ , de Feyter P, va
15.Very Long Sirolimus-Eluting Stent Implantation for de novo Coronary LesionsDegertekin M, Arampatzis A, Lemos P, Saia F, Hoye A, Tanabe K, Daemen J, Liu TK, McFadden E, Sianos G, Hofma SH, Smits PC, Van Der Giessen WJ, De Feyter P, Serruys PW.(Am J Card
16.Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusionsHoye A, Tanabe K, Lemos PA, Aoki J, Saia F, Arampatzis C, Degertekin M, Hofma SH, Sianos G, McFadden E, van der Giessen WJ, Smits
17.Treatment of very small vessels with 2.25-mm diameter sirolimus-eluting stents (from the RESEARCH registry)Lemos PA, Arampatzis CA, Saia F, Hoye A, Degertekin M, Tanabe K, Lee CH,Cummins P, Smits PC, McFadden E, Sianos G, de Feyter P, van der Giesse
18.Intravascular ultrasound evaluation after sirolimus eluting stent implantation for de novo and in-stent restenosis lesionsDegertekin M, Lemos PA, Lee CH, Tanabe K, Sousa JE, Abizaid A, Regar E,Sianos G, van der Giessen WJ, de Feyter PJ, Wuelfert E, Pop
19.Vascular responses at proximal and distal edges of paclitaxel-eluting stents: serial intravascular ultrasound analysis from the TAXUS IISerruys PW, Degertekin M, Tanabe K, Russell ME, Guagliumi G, Webb J, Hamburger J, Rutsch W, Kaiser C, Whitbourn R, C
20.Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World.” The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) RegistryLemos PA, Serruys PW, Van Domburg RT,
21.Chronic Arterial Responses to Polymer-Controlled Paclitaxel-Eluting Stents.Comparison With Bare Metal Stents by Serial Intravascular Ultrasound Analyses: Data From the Randomized TAXUS-II TrialTanabe K, Serruys PW, Degertekin M, Guagliumi G, Grube E, C
22.Retrospective image-based gating of intracoronary ultrasound images for improved quantitative analysis: The intelligate methodDe Winter SA, Hamer R, Degertekin M, Tanabe K, Lemos PA, Serruys PW, Roelandt JR, Bruining N.(Catheter Cardiovasc Interv. 20
23.Impact of different anatomical pattern of left main coronary stenting on long-term follow-upLee CH , Degertekin M , Domburg RT, Foley DP, Smits P, Giessen W, Vos J, de Feyter P, Serruys PW.(Am J Cardiol. 2003 Sep 15; 92(6):718-20.)
24.Coronary Restenosis After Sirolimus-Eluting Stent Implantation. Morphological Description and Mechanistic Analysis From a Consecutive Series of CasesLemos PA, Saia F, Ligthart JM, Arampatzis CA, Sianos G, Tanabe K, Hoye A, Degertekin M, Daemen J, McFad
25.Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: a clinical and angiographic study.Saia F, Lemos PA, Lee CH, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Sianos G, Smits PC, McFadden E, Hofma SH, van der Giessen WJ, d
26.Effectiveness of sirolimus-eluting stent implantation for recurrent in-stent restenosis after brachytherapy.Saia F, Lemos PA, Sianos G, Degertekin M, Lee CH, Arampatzis CA, Hoye A, Tanabe K, Regar E, van der Giessen WJ, Smits PC, de Feyter P, Ligthart
27.Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis.Degertekin M, Serruys PW, Tanabe K, Lee CH, Sousa JE, Colombo A, Morice MC, Ligthart
28.Usefulness of percutaneous left ventricular assistance to support high-risk percutaneous coronary interventionsLemos PA, Cummins P, Lee CH, Degertekin M, Gardin M, Ottervanger JP, Vranckx P, de Feyter P, Serruys PW.(Am J Cardiol. 2003 Feb 15; 91(4):479
29.Usefulness of shear stress pattern in predicting neointima distribution in sirolimus-eluting stents in coronary arteries.Gijsen FJ, Oortman RM, Wentzel JJ, Schuurbiers JC, Tanabe K, Degertekin M, Ligthart JM, Thury A, de Feyter PJ, Serruys PW, Slager C
30.Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: a clinical and angiographic study.Saia F, Lemos PA, Lee CH, Arampatzis CA, Hoye A, Degertekin M, Tanabe K, Sianos G, Smits PC, McFadden E, Hofma SH, van der Giessen WJ, d
31.Evaluation of coronary remodeling after sirolimus eluting stent implantation by serial 3D-intravascular ultrasound .Degertekin M, Regar E, Tanabe K, Lemos P, Lee CH, Smits PC, de Feyter P, Sousa E, Abizaid A, Ligthart J, Serruys PW. (Am J Cardiol. 200
32.TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation.Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, van der Giessen WJ, Staberock M, de Feyter P, Muller R, Regar E
33.Early Outcome AfterSirolimus-Eluting Stent Implantation in Patients With Acute Coronary Syndromes Lemos PA, Lee CH, Degertekin M, Saia F, Tanabe K, Arampatzis C, Hoye A, Sianos G, Smits P C, Feyter P, van der Giessen W, Domburg R, Serruys PW(J Am Coll
34.Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease.Arampatzis CA, Lemos PA, Tanabe K, Hoye A, Degertekin M, Saia F, Lee CH, Ruiter A, McFadden E Sianos G, Smits PC, van der Giessen WJ, de Feijter P, van Domburg
35.Collateral formation in patients after percutaneous myocardialrevascularization: a mechanism for improvement?Lee CH, Smits PC, Tanabe K, Van Domburg RT, Degertekin M, Van Der Giessen W, Serruys PW.(J Invasive Cardiol. 2003 Sep; 15(9):488-90)
36.Sirolimus eluting stent for the treatment of complex in-stent restenosis : The first clinical experienceDegertekin M, Regar E, Tanabe K, Smits P, Foley DP, J Vos, der Giessen W, de Feyter PJ, Serruys PW. (J Am Coll Cardiol 2003 Jan 15; 41: 184-189)
37.Fate of side branches after coronary arterial sirolimus-eluting stent implantation.Tanabe K, Serruys PW, Degertekin M, Regar E, van Domburg RT, Sousa JE, Wulfert E, Morice MC. (Am J Cardiol. 2002 Nov 1; 90(9):937-941)
38.Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Regar E, Serruys PW, Bode C, Holubarsch C, G
39.Persistent inhibition of neointimal hyperplasia after sirolimus eluting stent implantation: Long-term (up to 2 years) Clinical, Angiographic and Intravascular Ultrasound Follow-upDegertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Smits P, J Vos,
40.Intravascular Ultrasound Findings in the Multicenter, Randomized, Double-Blind RAVELTrial. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa E, Colombo A, Guagliumi G, Wijns W, Lindeboom W, Ligthart J, Feyter PJ, Morice MC. (Circulation 2002; 10
43.Which Method Should be Used to Determine the Obesity, in Patients with Coronary Artery Disease? Sonmez K, Akcakoyun M, Akcay A, Demir D, Duran NE, Gencbay M, Degertekin M, Turan F.( Int. J. Obes. Relat. Metab. Disord, 2003; 27, 341-346 )
45.Contrast echoes detected during percutaneous mitral balloon commissurotomy with inoue balloons and their relation with cerebral microembolic signals. Gençbay M, Turan F, Degertekin M, Yaymacı B, Dindar I. (Angiology 1998: 49:909-14)
46.Microbubles associated with mechanical heart valves: Their relation with serum lactic dehydrogenase levelsGençbay M, Degertekin M,, Başaran Y, Turan F.(Am Heart J 1999; 137:463-468)
47.Less invasive approach for closed mitral commissurotomyAkıncı E, Degertekin M,,Güler M, Dağlar B, Bozbuğa N, Berki T, Yakut C. (Eur J Cardiothoracic Surg 1998; 14: 274-8)
48.High Prevalence of Hypercoagulable States in Patients with RecurrentThrombosis of Mechanical Heart ValvesGençbay M, Turan F, Degertekin M, Ekşi N, Mutlu B, Unalp A. (J Heart Valve Disease 1998; 7: 601-609)
49.Application of proximal isovelocity surface area method to determine prosthetic mitral valve areaDegertekin M, Gençbay M, Başaran Y, Duran I, Yılmaz H, Dindar I, Turan F.(Journal of the American Society of Echocardiography 1998;11:1056-63)
50.Prevalence of microbubles associated with mechanical prosthetic cardiac valves: A prospective transesophageal echocardiographic studyGençbay M, Turan F, Yaymacı B, Degertekin M, Başaran Y, Dindar I, İzgi A.(The Journal of Heart Valve Disease 1998; 7:3
51.Validation of flow convergence region method in assessing mitral valve area in the course of transthoracic and transesophageal echocardiographic studies.Degertekin M, Başaran Y, Gençbay M, Yaymacı B, Dindar I, Turan F.(Am Heart J 1998; 135:207-14)